Tau proteins and MAPT — shaping neural stability
Biogen’s tau-targeting drug diranersen has shown potential in reducing tau levels and slowing cognitive decline in a small subset of a 400-person study, prompting plans for a larger trial. The results, presented at the Alzheimer’s Association International Conference in London, are cautiously optimistic but require confirmation in bigger studies.